10:20 am Earnings estimates: Drug major Sun Pharma’s third quarter profit is seen rising 27.4 percent year-on-year to Rs 1,804.6 crore, aided by operational performance. According to average of estimates of analysts polled by CNBC-TV18, revenue during the quarter may increase 11.6 percent year-on-year to Rs 7,905.3 crore, driven by Sun’s authorised generic (AG) launches of Daichi Sankyo drugs in US.

Blood pressure drug Benicar, Benicar HCT, Azor and Tribenzor are the AG launches of Daiichi. Market size of these drugs is USD 2.5 billion.

Analysts say AG sales will offset price erosion that Sun Pharma will face in cancer drug Gleevec generic. Gleevec generic sales are expected to fall around 30 percent QoQ to USD 45 million.

Source: moneycontrol.com